about
Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study.Pdx1 expression in Irs2-deficient mouse beta-cells is regulated in a strain-dependent manner.Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.Efficacy and safety of the GPR119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study.GPR119 Agonist DS-8500a Effects on Pancreatic β-Cells in Japanese Type 2 Diabetes Mellitus Patients.Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males.Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study
P50
Q42699213-DF4D4081-82D4-4F91-BA25-1A3322CB3C37Q44517501-E246C768-F5D4-40C5-9C72-CFEAD89DE707Q51246350-23C1F8F4-FF6B-4298-B00C-F8C66F0AD1D4Q51731154-357EBBFB-C120-4D5D-91E1-0C69126C7E5BQ52602460-E179004E-47A1-4143-A6CE-311EAAD04F09Q52628839-F2763A7E-F8AE-4454-A959-90991E2F1467Q89396904-34E87FCA-CA23-49BA-B155-C757E8F9D40A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Takashi Taguchi
@ast
Takashi Taguchi
@en
Takashi Taguchi
@es
Takashi Taguchi
@nl
Takashi Taguchi
@sl
type
label
Takashi Taguchi
@ast
Takashi Taguchi
@en
Takashi Taguchi
@es
Takashi Taguchi
@nl
Takashi Taguchi
@sl
prefLabel
Takashi Taguchi
@ast
Takashi Taguchi
@en
Takashi Taguchi
@es
Takashi Taguchi
@nl
Takashi Taguchi
@sl
P106
P31
P496
0000-0003-1019-2619